TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20226646

Group type: EXPERIMENTAL
Intervention: e-MiniAQLQ
Number of subjects: 40

Group type: COMPARATOR
Intervention: p-MiniAQLQ
Number of subjects: 40
Study: 18549913

Group type: EXPERIMENTAL
Intervention: Oxypurinol (600 mg/day)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 15772318

Group type: EXPERIMENTAL
Intervention: SP + CQ
Number of subjects: 280

Group type: COMPARATOR
Intervention: SP
Number of subjects: 280
Study: 12203176

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secular trend
Number of subjects: 0
Study: 10893069

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: MTHFR C677T mutation
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Young patients (age < 50 years)
Number of subjects: 116
Study: 8964276

Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg (LTG 100)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg (LTG 200)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Carbamazepine 600 mg (CBZ 600)
Number of subjects: 343
Study: 2056904

Group type: EXPERIMENTAL
Intervention: 7.2% glucose polymer‐electrolyte beverage (GP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Flavored sweetened placebo drink (SP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tap water (TW)
Number of subjects: 49
Study: 7046680

Group type: EXPERIMENTAL
Intervention: Relaxation training program
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study: 31332820

Group type: EXPERIMENTAL
Intervention: Ilaprazole 30 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Esomeprazole 80 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg followed by 10 mg once daily for 2 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg twice daily for 3 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ilaprazole infusion
Number of subjects: 48
Study: 27534671

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate therapy
Number of subjects: 157
Study: 26821931

Group type: EXPERIMENTAL
Intervention: lenalidomide plus low-dose dexamethasone (Rd)
Number of subjects: 80
Study: 24957533

Group type: EXPERIMENTAL
Intervention: Planned delivery at 37 weeks (group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Expectant management (group B)
Number of subjects: 76
Study: 22354905

Group type: EXPERIMENTAL
Intervention: Progressively reduced nicotine content cigarettes
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (smoked their own brand of cigarettes)
Number of subjects: 135
Study: 20808204

Group type: EXPERIMENTAL
Intervention: Prednisone (1.5 mg/kg per day for 2 weeks then 0.75 mg/kg per day for 2 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 110
Study: 17287417

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Avandia, 4 mg twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15639724

Group type: EXPERIMENTAL
Intervention: First line therapy with carboplatin and paclitaxel
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: High baseline performance status
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Non-squamous histology
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Two or more cycles of therapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Four or more cycles of therapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Grade 2 or greater neuropathy
Number of subjects: 230
Study: 14592237

Group type: EXPERIMENTAL
Intervention: Physiological dose of melatonin (0.14 mg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Supraphysiological dose of melatonin (2.2 mg)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 9988788

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estradiol valerate 2 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyclic estrogen/sequential progestogen regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous estrogen/sequential progestogen regimen
Number of subjects: 60
Study: 7901531

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) treatment
Number of subjects: 5
Study: 3315272

Group type: EXPERIMENTAL
Intervention: Theo-24 once-daily at 1500 hr
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theo-24 once-daily at 2100 hr
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theo-24 treatment (irrespective of dosing time)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theo-24 dosing at 1500 or 2100 hr
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theo-24 at 1500 hr
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31530653

Group type: EXPERIMENTAL
Intervention: e-Consent process
Number of subjects: 60
Study: 30032940

Group type: COMPARATOR
Intervention: EMA + Dashboard (self-directed condition)
Number of subjects: 34

Group type: COMPARATOR
Intervention: EMA + Dashboard + Counselor (counselor-supported condition)
Number of subjects: 34
Study: 27474885

Group type: EXPERIMENTAL
Intervention: High Protein Pasta (16 g protein, 6 g fiber)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High Fiber Pasta (11 g protein, 8 g fiber)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Pasta (11 g protein, 6 g fiber)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High Protein Pasta
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High Fiber Pasta
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Pasta
Number of subjects: 36
Study: 24508492

Group type: EXPERIMENTAL
Intervention: Baseline MR‐proADM concentrations
Number of subjects: 7863

Group type: EXPERIMENTAL
Intervention: Increase in MR‐proADM after one year
Number of subjects: 7863

Group type: EXPERIMENTAL
Intervention: Change in MR‐proADM
Number of subjects: 7863
Study: 23149928

Group type: EXPERIMENTAL
Intervention: Hydroxybupropion concentrations (per μg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion dosing to achieve hydroxybupropion level of 0.7 μg/ml
Number of subjects: 0
Study: 20735794

Group type: EXPERIMENTAL
Intervention: Tuning in to Kids parenting program (6 sessions + 2 booster sessions)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 216
Study: 18614723

Group type: EXPERIMENTAL
Intervention: Endurance exercise performed 17 h before high-sugar-food ingestion
Number of subjects: 13

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 13
Study: 15678250

Group type: EXPERIMENTAL
Intervention: HR (0‐[beta‐hydroxyethyl]‐rutosides) 2 g/day for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: D+H (diosmin+hesperidin) 500 mg tablet 3 times daily for 8 weeks
Number of subjects: 90
Study: 12071235

Group type: EXPERIMENTAL
Intervention: Iontophoretic application of lidocaine (60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous lidocaine (40 mg)
Number of subjects: 0
Study: 10072218

Group type: EXPERIMENTAL
Intervention: Perindoprilat
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Perindoprilat (in LV dysfunction subgroup)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Perindoprilat (in normal LV function subgroup)
Number of subjects: 25
Study: 8909084

Group type: EXPERIMENTAL
Intervention: Aftercare group therapy during inpatient treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intensive treatment with aftercare orientation and treatment contract
Number of subjects: 26
Study: 6353431

Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 138
Study: 30306334

Group type: EXPERIMENTAL
Intervention: Bone-anchored maxillary protraction therapy (BAMP) for 18 months
Number of subjects: 18
Study: 28933876

Group type: EXPERIMENTAL
Intervention: Infant iron-deficient anemia (IDA)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Limited caregiver responsiveness and stimulation
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Peer rejection at age 10
Number of subjects: 873
Study: 24870830

Group type: EXPERIMENTAL
Intervention: News stories that mention alcohol as a causative factor
Number of subjects: 60

Group type: COMPARATOR
Intervention: News stories that do not mention alcohol as a causative factor
Number of subjects: 60
Study: 25163547

Group type: EXPERIMENTAL
Intervention: Biological mesh closure of the pelvic floor after eAPR
Number of subjects: 104

Group type: COMPARATOR
Intervention: Primary perineal wound closure
Number of subjects: 104
Study: 22575355

Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 19944917

Group type: EXPERIMENTAL
Intervention: Platica (small-group discussions led by a health promoter)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Media (culturally tailored mailer)
Number of subjects: 231
Study: 17242632

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) for 7 days starting 1 week after surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no raloxifene)
Number of subjects: 10
Study: 15342900

Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg, 2 doses, intramuscular injection, 24 hours apart)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 11434939

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily (QD)
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% twice daily (BID)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily (BID)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Bimatoprost QD vs Timolol
Number of subjects: 1198
Study: 9884940

Group type: EXPERIMENTAL
Intervention: Modified in vitro method 1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified in vitro method 2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: In vitro method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: In vitro labeled RBCs through Hickman catheters
Number of subjects: 30
Study: 10411845

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472

Group type: COMPARATOR
Intervention: Pravastatin vs Placebo
Number of subjects: 472
Study: 2192554

Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride (Imodium A‐D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attapulgite (Diasorb)
Number of subjects: 0
Study: 32949

Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam, Hyoscine butylbromide, Ispaghula husk (all three agents)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: One or two of the potent preparations (Lorazepam, Hyoscine butylbromide, Ispaghula husk)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dummy preparations (control)
Number of subjects: 12
Study: 31120381

Group type: EXPERIMENTAL
Intervention: Contacted by the social worker
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Social worker assistance
Number of subjects: 172
Study: 28219917

Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate (ISDN)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate + Hydralazine (ISDN+hydral)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 25588441

Group type: EXPERIMENTAL
Intervention: Non-sterile clean boxed gloves
Number of subjects: 493

Group type: COMPARATOR
Intervention: Sterile gloves
Number of subjects: 493
Study: 23785451

Group type: EXPERIMENTAL
Intervention: Interactive sexual risk intervention
Number of subjects: 584

Group type: COMPARATOR
Intervention: Didactic sexual risk intervention
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Interactive injection risk intervention
Number of subjects: 584

Group type: COMPARATOR
Intervention: Didactic injection risk intervention
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Both interventions in Tijuana
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Access to syringes and condoms in Tijuana
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Access to syringes and condoms in Juarez
Number of subjects: 584
Study: 22864014

Group type: EXPERIMENTAL
Intervention: Simulation-based training using simulated patients and simulated gynecologic models
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 56
Study: 19864187

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention (self‐administered questionnaire)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 81
Study: 17285406

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg, 30 mg, or 45 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 200
Study: 15369509

Group type: EXPERIMENTAL
Intervention: RS-arm (two NRTIs + ritonavir + saquinavir)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: NN-arm (two NRTIs + nevirapine + nelfinavir)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: ASD-arm (abacavir + stavudine + didanosine)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Treatment interruption or poor adherence
Number of subjects: 293
Study: 11316407

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Converted to open appendicectomy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 500
Study: 9532621

Group type: EXPERIMENTAL
Intervention: Correct KR (Knowledge of Results)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erroneous (+100 ms) KR
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 trials of correct KR followed by 50 trials of erroneous KR
Number of subjects: 40

Group type: COMPARATOR
Intervention: No KR (Knowledge of Results)
Number of subjects: 40
Study: 7975772

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Basic bismuth salicylate (BSS)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Basic bismuth gallate (BSG)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Basic bismuth carbonate (BSC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bismuth aluminate (BA)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Basic bismuth nitrate (BSN)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Basic bismuth nitrate (BSN1480)
Number of subjects: 5
Study: 3393494

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 123
Study: 30689617

Group type: EXPERIMENTAL
Intervention: Unilateral intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CODS test practice)
Number of subjects: 10
Study: 28712129

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25986647

Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance treatment (BMT) with 12-step meeting attendance
Number of subjects: 300
Study: 23754097

Group type: EXPERIMENTAL
Intervention: Low Intensity (LO) interval training (60-80% W max)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) interval training (80-90% W max)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study: 21524003

Group type: EXPERIMENTAL
Intervention: Preventive programme for gingivitis prevention in children with fixed orthodontic appliances
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no preventive programme)
Number of subjects: 80
Study: 20102058

Group type: EXPERIMENTAL
Intervention: Valsartane (AT II blocker)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Niphedipine (calcium channel blocker)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Comparison between valsartane and niphedipine
Number of subjects: 69
Study: 16769613

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 14982362

Group type: EXPERIMENTAL
Intervention: Mini-implants (both miniplates and freestanding miniscrews)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Miniplates
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Posterior mandible location
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nonkeratinized mucosa surrounding implants
Number of subjects: 44
Study: 11352886

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GSNO
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9284739

Group type: EXPERIMENTAL
Intervention: 5 mg/day alendronate (A5)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 10 mg/day alendronate (A10)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (CE)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Calcium carbonate (500 mg/day)
Number of subjects: 74
Study: 8406294

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3942084

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (0.3 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No riboflavin supplementation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Human milk samples
Number of subjects: 39
Study: 30817388

Group type: EXPERIMENTAL
Intervention: Tight glucose control with a protocol including frequent, accurate glucose measurements and avoiding large glucose fluctuations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tight glucose control
Number of subjects: 0
Study: 29314218

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 29
Study: 26186951

Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg and trospium 5 mg with tamsulosin 0.4 mg for 2 months
Number of subjects: 338

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg only
Number of subjects: 338
Study: 25457927

Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Education subsidy
Number of subjects: 436
Study: 22192849

Group type: EXPERIMENTAL
Intervention: Liquid, aluminum-adjuvanted V710 (30 μg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Liquid, non-adjuvanted V710 (30 μg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted lyophilized V710 (60 μg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 115
Study: 20140620

Group type: EXPERIMENTAL
Intervention: Subcutaneous Redon drain
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group without a drain
Number of subjects: 200
Study: 18049940

Group type: EXPERIMENTAL
Intervention: Soy supplementation for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Equol-producing women
Number of subjects: 40
Study: 16280425

Group type: COMPARATOR
Intervention: Step I diet (30% fat with 9% SFAs)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Step II diet (25% fat with 6% SFAs)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: AAD (38% fat and 14% SFAs)
Number of subjects: 86
Study: 12064499

Group type: EXPERIMENTAL
Intervention: Adhesive resin system (Scotchbond MultiPurpose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 48
Study: 9477005

Group type: EXPERIMENTAL
Intervention: Midazolam (6.1 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flumazenil (benzodiazepine antagonist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 8688987

Group type: EXPERIMENTAL
Intervention: Chlorphenamine (CPA) regular release tablet (Histop) 4 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Reference formulation (Piriton) 4 mg
Number of subjects: 13
Study: 2203322

Group type: EXPERIMENTAL
Intervention: Psyllium (5.1 g, twice daily for 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (cellulose, twice daily for 16 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Psyllium and Placebo)
Number of subjects: 0
Study: 27948

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 41
Study: 30662336

Group type: EXPERIMENTAL
Intervention: Naturalistic light (IU)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard indoor lighting (CU)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (IU and CU)
Number of subjects: 43
Study: 28314319

Group type: EXPERIMENTAL
Intervention: Genexol-PM (100 mg/m2) and gemcitabine (1,000 mg/m2)
Number of subjects: 39
Study: 25975045

Group type: EXPERIMENTAL
Intervention: Acu‐TENS
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (sham electrical stimulation)
Number of subjects: 90
Study: 23289920

Group type: EXPERIMENTAL
Intervention: Single-dose nitazoxanide (1,000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitazoxanide-albendazole combination (1,000 mg-400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20358359

Group type: EXPERIMENTAL
Intervention: Nurse case-manager
Number of subjects: 46

Group type: COMPARATOR
Intervention: Multifaceted intervention
Number of subjects: 46